Home

Masuoka K. Lorianne

CIK 1466086 · Chief Medical Officer · last filed 2024-01-23

Masuoka K. Lorianne is a Chief Medical Officer who has filed 12 SEC Form 4 insider transactions across 5 companies since 2010. The most recent filing, for DMAC, was dated Jan 23, 2024.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

12

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O NEKTAR THERAPEUTICS
201 INDUSTRIAL ROAD
SAN CARLOS, CA 94070
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DMAC Chief Medical Officer 0 $6.47 $0 $0 1 2024-01-23
OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Director 2,000 $20.65 $41.3K $0 4 2023-03-03
MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted Chief Medical Officer — $0.55 — $0 3 2019-08-23
INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV) Delisted Chief Medical Officer — $0.32 — $0 1 2015-12-11
NKTR Chief Medical Officer — $69.76 — $0 2 2011-02-10

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-01-23 DMAC Grant (A) — $0 EDGAR
2023-03-03 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Mixed −4,000 -$80.0K EDGAR
2022-06-14 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Grant (A) +2,000 $0 EDGAR
2021-06-16 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Grant (A) +2,000 $0 EDGAR
2021-03-22 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Grant (A) — $0 EDGAR
2019-08-23 MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted Grant (A) — $0 EDGAR
2019-02-28 MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted Grant (A) — $0 EDGAR
2017-12-08 MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted Grant (A) — $0 EDGAR
2015-12-11 INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV) Delisted Grant (A) — $0 EDGAR
2015-03-04 — Grant (A) — $0
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.